# SEED Therapeutics

> SEED Therapeutics is a clinical-stage biotechnology company pioneering rationally designed molecular glue degraders to treat diseases driven by proteins long considered undruggable. Powered by its proprietary RITE3 discovery platform - which pairs disease-causing target proteins with the most suitable of more than 600 human E3 ligases - SEED reprograms the cell's own ubiquitin-proteasome system to destroy harmful proteins rather than merely block them. Founded in 2020 by CEO Lan Huang and a group of protein-degradation pioneers including Nobel laureate Avram Hershko, the company advanced its lead oral RBM39 degrader ST-01156 into first-in-human Phase 1 trials in early 2026, with a broader pipeline spanning oncology, neurodegeneration, immunology and virology backed by partners Eli Lilly and Eisai.

- **Founded:** 2020
- **Headquarters:** New York, New York, United States
- **Founders:** Lan Huang (Co-Founder, Chairman & CEO), Avram Hershko (Co-Founder (Nobel Laureate)), Ning Zheng (Co-Founder (Scientific)), Michele Pagano (Co-Founder (Scientific))
- **Team size:** ~25 employees
- **Products:** RITE3 Discovery Platform, ST-01156 (RBM39 Degrader), Tau Degrader Program, Immunology & Additional Programs
- **Notable:** Advanced lead candidate ST-01156 into first-in-human Phase 1 trials, dosing first patient in January 2026., FDA cleared the IND for ST-01156, which also earned Orphan Drug and Rare Pediatric Disease designations for Ewing sarcoma., Built the RITE3 platform capable of pairing targets with 600+ human E3 ligases, versus the two commonly exploited by the field.

## Products & services

- **RITE3 Discovery Platform** — Proprietary targeted protein degradation platform that systematically identifies optimal E3 ligase-target pairs and designs custom molecular glues, accessing 600+ human ligases rather than the small handful used by most competitors.
- **ST-01156 (RBM39 Degrader)** — Lead clinical candidate: an oral, brain-penetrant molecular glue degrader of RBM39, a regulator of RNA splicing overexpressed in many cancers. In first-in-human Phase 1 dose-escalation for advanced solid tumors including Ewing sarcoma, KRAS-mutant cancers and hepatocellular carcinoma.
- **Tau Degrader Program** — Preclinical neurodegeneration program developing a degrader of tau protein, a driver of Alzheimer's and other neurodegenerative diseases.
- **Immunology & Additional Programs** — A pipeline of additional molecular glue programs across immunology, virology and oncology, several supported by strategic partners Eli Lilly and Eisai.

## Achievements

- Advanced lead candidate ST-01156 into first-in-human Phase 1 trials, dosing first patient in January 2026.
- FDA cleared the IND for ST-01156, which also earned Orphan Drug and Rare Pediatric Disease designations for Ewing sarcoma.
- Built the RITE3 platform capable of pairing targets with 600+ human E3 ligases, versus the two commonly exploited by the field.
- Secured Eli Lilly as a cornerstone investor and collaborator from inception, plus a partnership with Eisai.
- Grew a pipeline to nine programs spanning oncology, neurodegeneration, immunology and virology.
- Founding team includes 2004 Nobel laureate Avram Hershko and the scientist who coined the term 'molecular glue.'

## Latest updates

- **2026-06** — Presented clinical advancement and broad oncology potential of ST-01156 in first-in-human Phase 1 studies at ASCO 2026.
- **2026-01** — Dosed first patient in Phase 1a dose-escalation study of oral RBM39 degrader ST-01156 in advanced solid tumors.
- **2025-09** — Completed $30 million Series A-3 financing.
- **2025-05** — Highlighted breakthrough advances in targeted protein degradation at AACR 2025.

## Links

- Website: https://seedtherapeutics.com
- LinkedIn: https://www.linkedin.com/company/seed-therapeutics
- Twitter/X: https://x.com/seedtx

---

Profile page: https://yespress.io/seed-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-07-18